PDCD1 and head and neck squamous cell carcinoma: A recent systematic review and meta-analysis of seven phase I, II, and III trials has demonstrated that combination therapy results in a significantly improved ORRs and one-year overall survival when compared to anti-PD-1 monotherapy in HPV-negative recurrent or metastatic HNSCC.